Meihua International Medical Technologies Facilitates World's Second* 5G Remote Robot-Assisted Lobectomy
Meihua International Medical Technologies (NASDAQ: MHUA) announced its NT-2000 surgical path analysis system supported the world's second 5G remote robot-assisted lobectomy, believed to be the first in China's Yangzi Delta area. The procedure was performed on July 15, 2024, at Yangzhou University Affiliated Hospital by a team from Shanghai Chest Hospital, over 200 kilometers away. MHUA's Chairman, Yongjun Liu, highlighted the operation's success, completed in just one hour using 5G technology and robotic precision.
The company is developing robotic surgical systems as part of its strategy to increase high-end product sales and expand its customer base. MHUA has introduced overseas technologies and established an R&D team focused on robotic-assisted surgery (RAS) systems. The RAS project, in collaboration with Hope City Medical Park in Hainan province, is expected to be completed in fall 2025.
Meihua International Medical Technologies (NASDAQ: MHUA) ha annunciato che il suo sistema di analisi del percorso chirurgico NT-2000 ha supportato la seconda lobectomia assistita da robot a distanza 5G al mondo, ritenuta la prima nella zona del Delta dello Yangzi in Cina. L'intervento è stato eseguito il 15 luglio 2024, presso l'Ospedale Universitario di Yangzhou, da un team dell'Ospedale Toracico di Shanghai, a oltre 200 chilometri di distanza. Il Presidente di MHUA, Yongjun Liu, ha messo in evidenza il successo dell'operazione, completata in appena un'ora utilizzando tecnologia 5G e precisione robotica.
La compagnia sta sviluppando sistemi chirurgici robotici come parte della sua strategia per aumentare le vendite di prodotti di alta gamma ed espandere la sua base clienti. MHUA ha introdotto tecnologie estere e ha costituito un team di R&D focalizzato sui sistemi di chirurgia assistita da robot (RAS). Il progetto RAS, in collaborazione con il Hope City Medical Park nella provincia di Hainan, dovrebbe essere completato nell'autunno del 2025.
Meihua International Medical Technologies (NASDAQ: MHUA) anunció que su sistema de análisis de trayectorias quirúrgicas NT-2000 respaldó la segunda lobectomía asistida por robot a distancia 5G en el mundo, considerada la primera en la zona del Delta del Yangtsé en China. El procedimiento se realizó el 15 de julio de 2024, en el Hospital Universitario de Yangzhou, por un equipo del Hospital Torácico de Shanghái, ubicado a más de 200 kilómetros de distancia. El presidente de MHUA, Yongjun Liu, destacó el éxito de la operación, que se completó en apenas una hora utilizando tecnología 5G y precisión robótica.
La empresa está desarrollando sistemas quirúrgicos robóticos como parte de su estrategia para aumentar las ventas de productos de alta gama y expandir su base de clientes. MHUA ha introducido tecnologías extranjeras y ha establecido un equipo de I+D centrado en sistemas de cirugía asistida por robot (RAS). Se espera que el proyecto RAS, en colaboración con el Hope City Medical Park en la provincia de Hainan, se complete en otoño de 2025.
Meihua International Medical Technologies (NASDAQ: MHUA)는 NT-2000 수술 경로 분석 시스템이 세계 두 번째 5G 원격 로봇 보조 폐엽 절제술을 지원했으며, 이는 중국 양쯔 강 델타 지역에서는 최초로 여겨진다고 발표했습니다. 이 절차는 2024년 7월 15일 양저우 대학교 부속 병원에서 상하이 흉부병원 팀에 의해 200킬로미터 이상 떨어진 곳에서 수행되었습니다. MHUA의 회장인 용준 리우는 5G 기술과 로봇의 정밀성을 이용하여 단 한 시간 만에 완수된 수술의 성공을 강조했습니다.
회사는 고급 제품 판매를 증가시키고 고객 기반을 확장하기 위한 전략의 일환으로 로봇 수술 시스템을 개발하고 있습니다. MHUA는 해외 기술을 도입하고 로봇 보조 수술(RAS) 시스템에 집중하는 R&D 팀을 구성했습니다. 하이난 성의 호프시티 의료 공원과 협력하여 진행되는 RAS 프로젝트는 2025년 가을에 완료될 예정입니다.
Meihua International Medical Technologies (NASDAQ: MHUA) a annoncé que son système d'analyse de trajectoires chirurgicales NT-2000 a soutenu la deuxième lobectomie assistée par robot à distance 5G au monde, considérée comme la première dans la région du Delta du Yangzi en Chine. La procédure a été réalisée le 15 juillet 2024 à l'Hôpital universitaire de Yangzhou par une équipe de l'Hôpital thoracique de Shanghai, situé à plus de 200 kilomètres de là. Le président de MHUA, Yongjun Liu, a souligné le succès de l'opération, réalisée en seulement une heure en utilisant la technologie 5G et la précision robotique.
L'entreprise développe des systèmes de chirurgie robotique dans le cadre de sa stratégie d'augmentation des ventes de produits haut de gamme et d'expansion de sa clientèle. MHUA a introduit des technologies étrangères et a constitué une équipe de R&D axée sur les systèmes de chirurgie assistée par robot (RAS). Le projet RAS, en collaboration avec le Hope City Medical Park dans la province de Hainan, devrait être achevé à l'automne 2025.
Meihua International Medical Technologies (NASDAQ: MHUA) gab bekannt, dass ihr NT-2000 chirurgisches Pfadanalyse-System die weltweit zweite 5G-remote-roboterassistierte Lobektomie unterstützte, die als die erste im Yangtze-Delta-Gebiet in China angesehen wird. Der Eingriff wurde am 15. Juli 2024 an der Yangzhou University Affiliated Hospital von einem Team des Shanghai Chest Hospital, das über 200 Kilometer entfernt war, durchgeführt. Der Vorsitzende von MHUA, Yongjun Liu, hob den Erfolg des Eingriffs hervor, der in nur einer Stunde unter Verwendung von 5G-Technologie und robotischer Präzision abgeschlossen wurde.
Das Unternehmen entwickelt chirurgische Robotersysteme als Teil seiner Strategie zur Steigerung des Verkaufs hochgradiger Produkte und zur Erweiterung seiner Kundenbasis. MHUA hat ausländische Technologien eingeführt und ein F&E-Team gegründet, das sich auf roboterassistierte Chirurgie (RAS) Systeme konzentriert. Das RAS-Projekt, in Zusammenarbeit mit dem Hope City Medical Park in der Provinz Hainan, soll im Herbst 2025 abgeschlossen sein.
- Successfully supported world's second 5G remote robot-assisted lobectomy
- NT-2000 system's real-time monitoring and guidance capabilities improve surgical accuracy
- Strategic initiative to increase sales of high-end products and broaden customer base
- Established dedicated R&D team for robotic-assisted surgery (RAS) systems
- RAS project in collaboration with Hope City Medical Park, expected completion in fall 2025
- None.
Meihua International Medical Technologies' involvement in the world's second 5G remote robot-assisted lobectomy marks a significant milestone in telemedicine and robotic surgery. The NT-2000 surgical path analysis system's role in this procedure underscores MHUA's growing presence in the high-end medical device market.
Key points to consider:
- The successful operation demonstrates the viability of remote robotic surgery, potentially revolutionizing access to specialized surgical care in underserved areas.
- MHUA's strategic focus on robotic-assisted surgery (RAS) systems aligns with the growing trend towards minimally invasive procedures, which offer benefits such as reduced risk and faster recovery times.
- The company's collaboration with Hope City Medical Park for RAS development suggests a commitment to long-term innovation in this space.
However, investors should note that while this achievement is impressive, it's still early days for remote robotic surgery. The technology's widespread adoption will depend on factors such as regulatory approvals, cost-effectiveness and healthcare infrastructure development. MHUA's ability to capitalize on this emerging market will be important for its future growth prospects.
MHUA's participation in this groundbreaking procedure signals its strategic positioning in China's evolving healthcare landscape. The company is smartly leveraging two key trends:
- The push for healthcare equality across regions, addressing the urban-rural divide in medical resources.
- The growing demand for advanced medical technologies in China's rapidly aging population.
By focusing on high-end products like the NT-2000 system, MHUA is targeting a lucrative segment of the medical device market. This move could potentially lead to higher profit margins and a more diversified revenue stream.
However, the success of this strategy hinges on several factors:
- The pace of 5G infrastructure development across China, especially in less developed areas.
- The willingness of hospitals and healthcare systems to invest in robotic surgery platforms.
- Competition from both domestic and international medical device manufacturers in the RAS space.
Investors should monitor MHUA's progress in commercializing its RAS technology and its ability to secure partnerships with major hospitals. The projected completion of the RAS project in fall 2025 provides a concrete timeline for assessing the company's execution of this strategic initiative.
YANGZHOU,
"We are honored that our cutting-edge technology could assist the advanced 3D imaging for surgical mapping in this sophisticated procedure," said Mr. Yongjun Liu, Chairman of Meihua, "Despite a physical distance of over 200 kilometers between the surgical team and the patient, the operation was executed seamlessly in just one hour, thanks to 5G technology and the precision of the robotic surgical system. We believe that robot-assisted surgery has made significant strides due to its clinical effectiveness, low risk, and quick recovery times. We also believe that successful implementations improve the quality of medical services, allowing patients to access diverse, personalized, and high-quality healthcare locally. We anticipate that this innovation will not only ease the workload on medical staff but also address disparities in medical resource distribution across
The development of Meihua's robotic surgical systems is part of the Company's strategic initiatives to increase sales of high-end products and broaden its customer base. The Company has introduced new overseas technologies, including minimally invasive surgical robot systems, and established a dedicated research and development team focused on robotic-assisted surgery (RAS) systems. The Company believes its NT-2000 system's real-time monitoring and guidance capabilities enable precise targeting of surgical sites, improving the accuracy and success rates of operations. The RAS project is being developed in conjunction with the Hope City Medical Park in
* We believe this is the World's second 5G remote robot-assisted lobectomy, as reported by Yangzhou University Affiliated Hospital: https://mp.weixin.qq.com/s/HuApwLs3V8rRib1nSpUMXQ and Yangzhou Daily: http://news.yznews.com.cn/2024-07/27/content_7674119.htm.
About Meihua International Medical Technologies Co., Ltd.
Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in
For more information, please visit www.meihuamed.com.
Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in
For investor and media inquiries, please contact:
IR Department
Email: secretary@meihuamed.com
Tel: +86-0514-89800199
Christensen
Yang Song
Email: yang.song@christensencomms.com
Tel: +86-010-59001548
View original content:https://www.prnewswire.com/news-releases/meihua-international-medical-technologies-facilitates-worlds-second-5g-remote-robot-assisted-lobectomy-302210979.html
SOURCE Meihua International Medical Technologies Co., Ltd.
FAQ
When did Meihua International Medical Technologies (MHUA) support the 5G remote robot-assisted lobectomy?
What is the significance of MHUA's NT-2000 surgical path analysis system?
When is MHUA's robotic-assisted surgery (RAS) project expected to be completed?